Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Withdrawal of disease-modifying therapies in inactive secondary progressive multiple sclerosis patients over 50 years
2018-001292-21Phase 3Active
- Sponsor
- CHU Rennes
- Start
- Jun 2018
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of interferon beta-1a, interferon beta-1b, glatiramer acetate, teriflunomide, dimethyl fumarate and 6 more in secondary-progressive multiple sclerosis (SPMS) (2 arms), sponsored by CHU Rennes. Primary endpoint: Disability progression at 2 years. Started Jun 2018; status: active.
02
Drugs
interferon beta-1ainterferon beta-1bglatiramer acetateteriflunomidedimethyl fumarate
03
Conditions
secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on 2018-001292-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001292-21.